A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)

Completed · Phase 1

Conditions studied: Healthy

In brief

The main goal of this study is to learn what happens to MK-6552 in a person's body over time (a pharmacokinetic or PK study). Researchers want to know what happens to MK-6552 in healthy adults when a single dose of MK-6552 is given with multiple doses of diltiazem. The researchers believe that multiple doses of diltiazem will not affect the highest amount of MK-6552 in the blood.

Key facts

Study ID

NCT06662396

Run by

Merck Sharp & Dohme LLC

People needed

14

Starts

2024-06-13

Expected to finish

2024-09-27

Last updated by the study team

2024-10-28

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The main inclusion criteria include but are not limited to the following:
• Is in good health before randomization
• Body Mass Index (BMI) between 18 and 32 kg/m\^2, inclusive

You may not qualify if…

• The main exclusion criteria include but are not limited to the following:
• History of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• History of cancer (malignancy)

Where it is running

• ICON (Site 0001) — Lenexa, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.